Ganetespib is under clinical development by Aldeyra Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ganetespib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ganetespib (STA-9090) is under development for the treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, malignant peripheral nerve sheath tumors, sarcomas, malignant pleural mesothelioma. The drug candidate is administered through intravenous route. It is a synthetic, small-molecule that acts by targeting heat shock protein 90 (Hsp90).
It was also under development for the treatment of coronavirus disease 2019 (COVID-19).
It was under development for the treatment of ocular melanoma, melanoma, hematological cancers including acute lymphoblastic leukemia, chronic myelogenous leukemia, post-transplant lymphoproliferative diseases, HER2 positive or triple negative breast cancer, squamous cell carcinoma of the head and neck (SCCHN) including oral cavity, oropharynx, larynx or hypopharynx, metastatic esophagogastric cancers, non-small cell lung cancer, relapsed and refractory small-cell lung cancer, metastatic colorectal cancer, rectal adenocarcinoma, gastrointestinal stromal tumor, hepatocellular carcinoma, metastatic pancreatic cancer, gastrointestinal carcinomas, non-squamous non-small cell lung carcinoma, urothelial carcinomas, relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer.
Aldeyra Therapeutics overview
Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic diseases caused by inborn errors of aldehyde metabolism. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Ganetespib’s drug-specific PTSR and LoA scores, buy the report here.